• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Comprehensive Accounts of Pharmaceutical Research and Development

Comprehensive Accounts of Pharmaceutical Research and Development

From Discovery to Late-Stage Process Development Volume 1

9780841231894
1,111.50 zł
1,000.35 zł Save 111.15 zł Tax included
Lowest price within 30 days before promotion: 1,000.35 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Until the latter part of the 19th century, the majority of known drugs were either herbs or extracts of active ingredients from botanical sources. At this point, the world witnessed two major cornerstone achievements that laid the foundation of modern drug discovery and development:: the emergence of pharmacology as a contemporary science through the work of Schmiedeberg (considered by many as the father of modern pharmacology) at the University of Strasbourg, and Wöhlerslandmark synthesis of urea from ammonium cyanate (the first synthesis of an organic molecule from an inorganic source) which heralded the birth of modern organic chemistry. Drug discovery has evolved from relying on luck, accident and serendipity to a complex endeavor that is at the interface of severaldisciplines (e.g. pharmacology, biology, chemistry), and is built on the understanding of mechanisms and causes of diseases. This book is produced to celebrate the evolution of drug discovery and development. It will prove useful to synthetic organic chemists in both pharmaceutical industry and in academia, and can serve as a teaching tool to students who want to learn and understand the processes and challenges of drug discovery and development with real examples from top pharmaceutical companies. The chapters contain citations of a large number of valuable selected references to the primary literature. The bookhighlights the tireless efforts of discovery and process chemists, and their roles in the advancement of drug discovery and development. The chapters presented in this book are written by a selected group of outstanding, very accomplished medicinal and process chemists with noted experiences and diverse backgrounds, representing some of the top pharmaceutical companies. The chapters highlight examples of emerging concepts, new developments and challenges arising in the discovery of new drug candidates and the development of new practical synthetic chemistry processes to produce these drug candidates on large scale. The discoveryof each drug or drug candidate is presented by the discovery chemist(s) and the process chemist(s) who developed the drug. These writing teams describe the drugs development to give the reader a complete story of drug discovery and development.
Product Details
OUP USA
85488
9780841231894
9780841231894

Data sheet

Publication date
2018
Issue number
1
Cover
hard cover
Pages count
350
Dimensions (mm)
152 x 227
Weight (g)
714
  • Preface; 1. Discovery and Chemical Development of Suvorexant - A Dual Orexin Antagonist for Sleep Disorder; 2. Discovery of Novel Protein Fucosylation Inhibitors and Development of a Manufacturing Process To Prepare Inhibitor 6,6,6-Trifluorofucose; 3. Development of Hsp90 Inhibitors for the Treatment of HER-2 Positive Solid Cancers; 4. Discovery of the Novel Oxadiazole-Containing 5-Lipoxygenase Activating Protein (FLAP) Inhibitor BI 665915; 5. Development of an Efficient Asymmetric Synthesis of the Chiral Quaternary 5-Lipoxygenase Activating Protein Inhibitor; 6. The Discovery and Process Chemistry Development of GDC-0084, a Brain Penetrating Inhibitor of PI3K and mTOR; 7. Discovery and Development of Doravirine: An Investigational Next Generation Non-Nucleside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV; 8. The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor; 9. Early and Late Stage Process Development for the Manufacture of Dacomitinib; 10. Discovery and Development of the Natural Product Derivative SPI-1865 as a Gamma Secretase Modulator for Alzheimers Disease: Part I; 11. Discovery and Development of the Natural Product Derivative SPI-1865 as a Gamma Secretase Modulator for Alzheimers Disease; 12. Telaprevir: From Drug Discovery to the Manufacture of Drug Substance; Editors Biographies; Indexes;
Comments (0)